Skip to main content
. 2020 Apr 14;2020(4):CD010599. doi: 10.1002/14651858.CD010599.pub2

Speich 2014.

Methods Design: parallel group randomized trial
Duration of study: September to November 2012
Follow‐up: 18–23 days
Participants Country: Tanzania
Setting: school
Number included in study: 480
Inclusion criteria: children who were positive for either T trichiura or hookworm
Age: 6–14 years
Sex: 247 boys, 233 women
Exclusion criteria: children who had any systemic illness (e.g. clinical malaria or hepatosplenic schistosomiasis), as assessed by a medical doctor at the initial clinical assessment
Lost at follow‐up: 22 (4.6%)
Number positive for A lumbricoides: 309
Number included in review: 143
Interventions Treatment strategy: screening and treat all included participants
  • Group 1: albendazole 400 mg single dose (n = 75)

  • Group 2: mebendazole 500 mg single dose (n = 68)

  • Group 3: oxantel pamoate 20 mg/kg + albendazole 400 mg (not included)

  • Group 4: oxantel pamoate 20 mg/kg (not included)

Outcomes Outcomes included:Ascaris prevalence pre‐ and post‐treatment, cure rate, pre‐ and post‐treatment GM epg, adverse events
Outcomes not included in review: oxantel pamoate, oxantel pamoate + albendazole efficacy for Ascaris, anthelminthic efficacy for T trichiura and hookworm
Notes Diagnostic technique: Kato‐Katz
Funding support: Medicor Foundation and the Swiss National Science Foundation
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence generation (selection bias) Unclear risk Quote: "Children were randomly assigned, with the use of block sizes of four, to receive one of four treatments."
Allocation concealment (selection bias) Unclear risk Details not reported.
Blinding of participants and personnel (performance bias) 
 All outcomes Low risk Quote: "Children, study‐site investigators were unaware of the study‐group assignments. In the first day children were given either oxantel pamoate or identical placebo tablets. On the second day, children were administered two tablets albendazole or placebo table plus mebendazole."
Blinding of outcome assessment (detection bias) 
 All outcomes Low risk Quote: "Laboratory technicians were unaware of the treatment assignments."
Incomplete outcome data (attrition bias) 
 All outcomes Low risk 22 (4.6%) participants lost at follow‐up and not included in analysis.
Selective reporting (reporting bias) Low risk All stated outcomes were reported.
Other bias Low risk No obvious source of other bias.